The biosimilar first-mover question has a clean theoretical answer and a messy empirical one. Theory says: get to market first, […]
Biosimilar First-Mover Advantage: What the Adalimumab Market Actually Taught Us Read Post »
Executive Summary Generic pharmaceutical companies face a structural cost squeeze that has worsened since 2016. Teva, Mylan, and Sun Pharma
A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis —
Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control
The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other
The United States pharmaceutical market operates within a network of opaque intermediaries that disconnect manufacturing costs from patient expenditures. Billionaire
Dunking on the Pharma Industry: An In-Depth Analysis of Mark Cuban’s War on Drug Prices Read Post »
1. Why Patent Defense Is a Corporate Strategy Problem, Not a Legal One Patent defense gets handed to legal teams.
1. Executive Summary The pharmaceutical industry’s API manufacturing layer is undergoing a structural break, not an upgrade cycle. The convergence
A deep-dive for pharma IP teams, portfolio managers, and institutional investors on the strategies, IP valuations, and commercial mechanics that
Drug Patent Challenges: Win the Market, Not Just the Lawsuit Read Post »
Sign in or create a free account to read this DrugPatentWatch article
